Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow! The stem cell chatter is about to become very loud very soon! This company is so undervalued! Buy em up! Imo
Stem cell transplant 'game changer' for MS patients
Results from an international trial show that it was able to stop the disease and improve symptoms.
https://www.google.com/amp/s/www.bbc.co.uk/news/amp/health-43435868
Thanks! Stem cell stocks are a big deal?!?! :)) Love seeing those articles and there will be many more. The chatter is increasing! Yes MORE REVENUE than many but with a MUCH LOWER MARKET CAP AND PPS than almost all! Rare that otc stocks move up to the BB but I could see this one making a move. Fact.
$USRM
IMO and what I have noticed this last year. When you see vert and cant on the ask (especially CANT) 80% of the time they are full of shit and almost never want to sell shares. They are being used as a tool to manipulate pps and try to get someone to sell to them on the bid. It’s like a rabbit trying to get out of it’s hole but someone keeps putting a lid over it. Eventually with enough rabbits (pressure) the lid comes off because really they don’t want to give up any shares and we have seen that for months. There will be a time where it makes no sense for them to even try. Slap those bastards! All Imo
Not many for sale down here. Huge loading zone! Eom
Once it turns the corner folks will want to be part of the next move. Many eyes are watching this stock and it will keep moving up. NOT MANY .05’s for sale!! Way to undervalued. Imo
DCA baby! We have big money loading this for years but wait until a few on Wall Street get a sniff of this emerging company. Regenerative med stocks will be the talk of the town and that’s what I’m waiting for! Snow ball effect into a boulder! Yee haw! Buy all you can. Imo
$USRM
Big next leg. Get em before she blows! Imo
$USRM
Vert is trying to cover. They know no one is selling down here. Slap his buddy vert on the ask! He won’t like that either I bet. Yes a1 way undervalued! Imo
$USRM
Slap CANT! Trust me he hates that. ;)
Nice job longs. May close green.
$USRM
Buy and hold easy! Big money lickin’ their chops for your shares. I know we have strong hands here! Regenerative medicine and USRM is the future! If you think otherwise sorry your wrong. This one is going up with or without you! Patience! $USRM
Exactly. We are already “trying” and succeeding! Going to be like MJ. States and the people will force federal law. In the meantime USRM will grow it’s stem cell empire! Imo
$USRM
$USRM you always buy the dip imo ;)
A bunch of my shares will qualify for long term tax now! So mine are set for Dollars! I feel the most patient here will make the most money. $USRM
For those that don’t know———>
U.S. Stem Cell, Inc. (OTC:USRM) is an emerging leader in the worldwide development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions. Based in Sunrise, Florida, the Company has developed a clinical protocol and kit— AdipoCellTM —that helps isolate a patient’s own stem cells while keeping them intact, in order to harness their healing ability for a wide variety of indications.
USRM also trains and certifies physicians from around the world in the administration of stem cell therapies and protocols — to date, more than 700+ physicians worldwide. The company is also in the process of opening standalone and partnered stem cell clinics — to date, four in the United States—and several worldwide.
There are two targeted stem cell products. USRM currently has in development for the repair of cardiac tissue: MyoCellR and MyoCell SVF-1TM— both of which are poised to go to the next phase of clinical development.
MyoCellR, a muscle stem cell therapy intended to improve cardiac function after heart attack, involves utilizing USRM’s proprietary cell-culturing process to isolate and expand muscle stem cells (myoblasts) to assist in combating scar tissue in order to improve cardiac function. Phase I, II and part one of a phase II/III trial have been completed; Part two of a Phase II/III is approved by the FDA and ready to begin patient enrollment.
MyoCell SDF-1, a more robust form of MyoCellR, involves using the same myoblast cells as in MyoCellR with the addition of a gene-modified adenovirus vector in order to release additional stromal derived factor 1, or SDF-1 protein. By modifying the myoblasts to express SDF-1 prior to injection, the levels of SDF proteins in the heart can increase. In preclinical studies, MyoCell SDF-1 provided a 54% improvement of cardiac function compared to a 27% improvement in the original MyoCell composition while the animal placebo control group declined 10%. Preclinical trials also demonstrated MyoCell SDF-1 has the potential to enhance blood vessel formation in damaged hearts. The IND application was approved by the FDA.
USRM is currently seeking partners to fully develop and commercialize these products, which have already demonstrated safety and efficacy in preliminary studies.
U.S. Stem Cell also has two product lines that are derivatives of its core work in humans: veterinary stem cell products, which have demonstrated marketability in the high-end equine market; and stem cell banking, a service that is a secondary business unit that helps facilitate its core competency of stem cell therapies.
For more information, please contact us.
Dr. William P. Murphy, Jr., M.D.
Chairman of the Board
Dr. William P. Murphy, Jr., currently serves the Chairman of the Board of U.S. Stem Cell, having joined the as a member of the Board of Directors in June 2003. A highly successful entrepreneur and inventor, the owner of 17 patents, a distinguished speaker and published author, Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was later acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which filed for involuntary bankruptcy in December 2003.
Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology. Dr. Murphy is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology and the Jay Malina Award from the Beacon Council, Miami-Dade County’s economic development arm.
Mike Tomás
President & CEO
Mike Tomás, President & CEO of U.S. Stem Cell Inc, (fka BioHeart), is considered by many in the industry as one of the most experienced marketers and operating executives for IT/Communications and Biotech/Life Sciences private equity and venture groups portfolio companies. The son of a serial entrepreneur, he spent nearly 20 years driving the evolution of telecommunications technology in the U.S. and Mexico in leadership roles ranging from sales, marketing, customer service, telemarketing, engineering, and operations. Upon retiring as Chief Marketing Officer of Avantel, MCI/Worldcom’s Global Ventures $1B investment with Banamex (at the time, the largest bank in Latin America), Mr Tomás joined other former-MCI executives (including MCI CEO Jerry Taylor) and helped raise venture capital to form an integrated customer communications software solution that was named on Red Herring magazine’s “Top Ten to Watch” list.
Upon the successful sale of that company in 2001, Mr Tomás helped launch The ASTRI Group, an early-stage private equity investment company providing capital, business development and strategic marketing support to emerging private companies. Mr Tomás sits on the boards of Rokk3r Labs (exponential technologies development and portfolio), Easy Solutions Total Fraud Protection (authentication, fraud prevention and anti-phishing countermeasures), U.S. Stem Cell (adult stem cell development and applications), The IDEA Center (Miami Dade College’s entrepreneurial institute), Career Source Florida (appointed by Florida Governor Rick Scott to his statewide workforce investment board) and is the current chairman of Florida International University’s Global Entrepreneurship Center. Mr Tomas is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner–and winner of top communications, medical innovations, education and entrepreneurial awards. An avid athlete, Mr Tomas is also a Miami-Dade County Sports Commissioner.
Kristin Comella, PhD
Chief Science Officer
Dr. Kristin Comella, USRM’s Chief Science Officer, has an extensive background in the study and implementation of stem cell therapy. As a student focusing on the mechanics and systems of the body in order to achieve optimal health, her more than 20+ years experience has given her notable training with experts in the stem cell arena. Her graduate studies and PhD course work at Ohio State University provided her the opportunity to work with Dr. Jeffery Chalmers to focus on the use of nano-particles magnets to isolate and separate cells. She then delved more deeply into biomedical engineering at the Cleveland Clinic and Osiris Therapeutics — a small start-up in Maryland — mentored company founded by the ‘father of Mesenchymal Stem Cells,’ Dr. Arnie Caplan. Her work at Osiris led in 2002 to one of the first IND approvals of stem cells in orthopedics from the FDA, and was the beginning of her zeroing in on stem cells and their application for healing.
Following her work at Osiris, Dr. Comella was offered the opportunity to work with Dr. Darwin Prockop, the Grandfather of cellular therapy research on mesenchymal progenitors, at Tulane University. Her responsibilities included managing the FDA GMP facility (good manufacturing practices) at Tulane’s Center of Gene Therapy, where she designed, implemented and administered the application of stem cell therapy for spinal cord injuries.
Her dedication to the advancement of stem cell therapy and regenerative medicine led her to what is now U.S. Stem Cell in 2004. The combination of Dr. Comella’s background, as well as the timing of the world’s need for and emerging understanding of the benefit of stem cell therapy, make USRM an opportunity whose time has come.
Mark P Borman
Mark Borman is a strategic, roll-up-your-sleeves CFO and Board Member with a passion for growing companies ranging from startup, private equity, IPO to publicly-traded. His forte is helping companies achieve strategic growth, profitability, cash-flow, capital-raising, and valuation goals. Mark’s performance-driven experiences were honed at NASDAQ- and NYSE-listed companies that three times nearly tripled sales. He has raised $7.5 billion in 12 offerings to finance rapid growth, acquisitions and strategic transformations through leveraged buyouts, IPO and secondary equity offerings, convertible note offerings, and exits with spinoffs into three new IPO companies, which were subsequently acquired. He received his MBA in Finance from the University of Chicago and his Bachelor’s degree in Accounting from Michigan State University. Borman is also a Certified Public Accountant and Chartered Financial Analyst.
Sheldon Anderson
Mr. Anderson is Chairman of the Florida Advisory Board of Northern Trust Corporation. From 1992 through December 31, 2012, Mr. Anderson served in a variety of executive capacities with Northern Trust Corporation, including his most recent position as Chairman and Chief executive Officer Southeast Region of Northern Trust Corporation. Mr. Anderson is the Chair-elect of the Beacon Council, Miami-Dade County’s economic development agency. He is a Board member of the Miami-Dade College Foundation, Inc.; Museum of Contemporary Art (MOCA); the New World Symphony; Baptist Health Systems Governing Board and Carrollton School of the Sacred Heart. He is Past Chair and a member of the Advisory Council of the United Way of Miami-Dade County. Anderson is President of the Board of Cleveland Orchestra Miami / Miami Music Association and also serves on the Advisory Board of the University of Miami School of Law for Ethics& Public Service. He is a member of the Orange Bowl Committee and the President’s Council of Florida International University. A Miami native, Sheldon holds a degree in International Studies from Ohio State University.
Greg Knutson
I have been in the Construction Industry for 47 Years. I am the President of G.E. Knutson Inc. a Concrete and Masonry Company which I personally started in 1987. Also I am the President and Founder of Sunwood Properties LLC which is my Property Management Company I started in 2008. Finally I am also a Managing Partner of G&G Land Development Co LLC which specializes in Residential Developments.
Yes great post! Just follow Murphy that dude knows his shit! “Stem Cells will change medicine like antibiotics did”! Go $USRM ZOOM ZOOM ;)
Yes sir and such strong hands here. Going to be a beast with this group imo!
$USRM
Not much for sale under .07.
$USRM
Biggest one imo is going to be a booming industry with limited number of stem cell stocks to pick from. THAT MULTIPLIER WILL BE A BIG ONE ! Folks want to talk about revs but you better not leave out that part of the equation! $USRM
CEO Blog: February 2018
Posted by U.S. Stem Cell, Inc
Dear Shareholders and Friends,
Thank you all so much for taking the time to learn more about our recent progress. In this post, we want to take a moment to share key highlights from 2017, as well as update you with new developments for 2018.
A strengthening economy, an increase in marketplace demand as more people learn about stem cell treatments and alternatives to opioids, and an increase in more doctors and physicians advancing their skill sets to include stem cell treatments are all reasons why we are beginning to see steady growth.
We are pleased to announce that our proprietary AdipocellTM stem cell kit has reached 10,000 units in sales — an indication that the marketplace is starting to demand stem cell therapy more readily. Although we reached the goal in January of 2018, much of the effort behind attaining that benchmark was done in 2017, and our hard work is paying off.
We are also proud to announce we have completed more than 10,000 stem cell procedures since 1999 for a variety of indications — including orthopedic, autoimmune, degenerative and neurological diseases. We are pleased to share that, to-date, we have trained more than 700 physicians worldwide on stem cell therapy, and we anticipate that number will only continue to increase.
The FDA’s issuance of guidance documents in November of last year also has also signaled to the marketplace the legitimacy of stem cell therapy as a practice. Because our science is based on the use of a patient’s own (autologous) stem cells, we are confident that the issuance of these guidance documents moves us closer to a time when there will be clear differentiation between treatments that are autologous, versus those that involve the use of donated, off-the-shelf, third-party stem cells that may or may not have been genetically manipulated and clearly require more regulation.
USRM is working with one of the best legal teams based in Washington, D.C., to help communicate with the FDA while preserving the rights of patients to harness their bodies’ own healing potential. We have joined forces with the Academy of Regenerative Practices to ensure that our physicians have a right to practice regenerative medicine with their consenting patients. We are proud sponsors of the upcoming ARP annual conference March 1st – 3rd where our Chief Science Officer Dr. Kristin Comella will be a keynote speaker.
Demand for stem cell therapy is anticipated to be at an all-time high this year, as more patients seek the growing trend of using their own cells to heal various injuries and diseases. As a result, we have expanded our clinic locations to include West Palm Beach. This expansion is timely, given the emerging and explosive demand now coming from patients and the marketplace. We have worked very hard as a team to temper our growth in order to be ready to meet the demands of a growing market at just the right time. We are confident that timing is now.
USRM technologies are now offered in six continents with interest from various countries throughout the world growing. We have experienced a few delays with our facilities opening in Kuwait due to unforeseen regulatory hurdles. These types of challenges are very familiar to us, we know it is part of the landscape and we know how to address them. We will continue to work with our legal team to neutralize these concerns and move forward with bringing stem cell treatments to the patients in the Middle East.
The recent opioid crisis in America means more patients are seeking alternative therapies to pharmaceuticals and surgery for coping with and managing chronic pain. Stem cell therapy may offer new solutions for these patients experiencing systemic diseases, orthopedic conditions, neurological symptoms and other therapies for an aging population. Shape Magazine discusses this subject in their most recent issue, where they mention Dr. Kristin Comella and her work with autologous stem cells. Shape Magazine is the first of many highly-visible mentions where Dr. Comella has been featured, including “The Healing Miracle: The Truth About Stem Cells,” a docuseries that interviews renowned experts in the field of stem cell medicine and explores in-depth the benefits and application of regenerative stem cell therapy. Dr. Comella is featured in Episode five of the docuseries; that interview can be viewed in its entirety here.
Due to the overwhelming response we have had as a result of that docuseries, we were inspired to launch our own live webinar series in order to educate and inform our audience, as well as provide a forum for Q & A on an anonymous platform. “Facts About Stem Cell Therapy,” which had its first live broadcast February 9th, was very well received and had more than 100 participants. Dr. Comella answered questions live for nearly two hours, which is another demonstration of the growing demand for information about this emerging, holistic, regenerative therapy. If you are interested in joining our mailing list to receive notification for our next stem cell webinar, click here.
In honor of Valentine’s Day and the month of love, our second webinar was broadcast live February 17th and featured Dr. Comella and fitness expert and world renown leading biohacker Ben Greenfield. The webinar, which is entitled “Enhancing Sexual Performance with Stem Cell Therapy,” provides the opportunity to learn more about stem cell therapy and enhancing sexual performance. Greenfield, who recently underwent penile enhancement with stem cell therapy, documented his journey in the January issue of Men’s Health magazine. He was successful at increasing both size and rate of performance. To listen to that webinar in its entirety click here.
Our commitment to this emerging science is unwavering and we will continue to expand efforts to help patients maximize their health with this amazing technology. We thank you for your interest and continued support and welcome the chance for an ongoing dialogue to answer any questions you may have.
Warmest regards,
Mike Tomas,
I see monsters lurking!! They are trying to manipulate to steal your shares. When big money is loading you buy! Imo
Big buyer(s) will be lurking to steal your shares. Buy and hold. Go USRM!
Meaning...folks aren’t “trading” this! Smart folks imo. RSI means nothing to me here. Long and strong USRM!
We have many investors here.
I think we need to be trading much much higher!! Go find me another .14 penny stock with innovative tech, proven results,fast growing revs and in a booming industry!! SHIT..go find me a DOLLAR one LOL!! Per brilliant Dr. Murphy in the Healing Mircale docuseries interview“stem cells will change medicine like antibiotics did!”
Stem Cell Testimonials and info:
http://usstemcellclinic.com/testimonials/
Former NBA John Salley
Great short newer video
Many seem intent on saying .25. Sure it will be there for a while and then go up. Some think short term like months which is small peanuts. I’m thinking long term like years for a really big money play. This has the potential imo. If you sell any buy em back if you can. ;) If large money is loading when will they stop?! How many shares do they want?! There are many factors that could blast this to high heaven. This may be my only opportunity for a huge runner. I see the potential and will be takin’ the chance. Glta
$USRM
It will go dollars. People will pay it easy. US Stem Cell will continue to be #1 stem cell stock to buy! Just be patient. Imo
$USRM
Big money loading!! Ohhh yeah!! Cheers USRMers!
I don’t see one but could be wrong. All I know is ascm and cant want a bunch more shares and they are battling for them. Vert is covering his ass off. Many I wish I had their count.
$USRM
Oh my..I see big funds battling for shares now. Hold em long folks!
$USRM
A few biggins’ soaking just a few of the retail sellers. Movin’ up soon here. Imo
Wow that is a big step forward! Keeps getting better! $USRM
http://stockcharts.com/h-sc/ui?s=USRM&p=D&yr=2&mn=0&dy=0&id=p20717929527
A few scanners may pop off tomorrow with the golden cross! Keep buying holding and churning folks. This is how we move it! Forward looking stock with much much more to come! Go USRM!
Stem Cell Testimonials and info:
http://usstemcellclinic.com/testimonials/
Former NBA John Salley
Great short newer video
Stem cell treatments and therapies are becoming mainstream world wide and USRM is a leader. Umm..US STEM CELL is at pennies. Exciting times ahead. Imo
$USRM
Some...shit I’m not selling one share here. I’ve done my research and I know this market cap is not even close to true value here. Imo
$USRM
http://stockcharts.com/h-sc/ui?s=USRM&p=D&yr=2&mn=0&dy=0&id=p20717929527
Look at that ACCUMULATION line! BUY HOLD WIN!
Future of Medicine! Do your DD on this one!
By the way I’m sure many of you caught that Comella reiterated this below at the ARP conference!!!!!!!! ;)
Myocell:
Comella states "Patients with treatment did about 100 METERS further in their exercise capacity or 6 min walk test"
"Bi ventricular pacing was APPROVED by the FDA with a 20 METER differential."
"Flag ship product is something that is showing a 5 TIMES greater improvement for what is considered the gold standard for heart failure patients".
https://singularityhub.com/2017/01/17/stem-cells-are-poised-to-change-health-and-medicine-forever/
$USRM
Just simply more demand than supply has driven the price up. Plus we only have had great news lately! Folks do their DD and say oh shit this seems way undervalued and hold. I am very interested to see how many shareholders we have from a year ago. Bet it went up big time!
$USRM
Big things coming! Buy and hold all you can! Way undervalued! This is truly a huge opportunity so take advantage of it! Imo
$USRM
About to break! Grab all you can!
$USRM
Yes sir. The big gains in the sector are great! Not only are we having fantastic quarters others are too! Many eyes are about to be arriving. Market Cap is way out of line here and a correction is coming! All imo.
$USRM